AKTS Stock — Aktis Oncology Inc.: Cash, EV, Pipeline

Share price

$21.88

Market cap

$1,217.0M

Cash

$517.3M

Enterprise value

$699.7M

Balance sheet

Cash	$517.3M
Debt	$0.0M
Net cash	$517.3M
Enterprise value	$699.7M
Basic shares	53.4M shares
Fully diluted shares	62.9M shares
Fully diluted market cap	$1,376.2M
Cash per share	$9.69

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AKTS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	[225Ac]Ac-AKY-1189 (therapeutic)	Phase 1	Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma	—
Jan 12 - Feb 23	[225Ac]Ac-AKY-2519 (therapeutic)	Phase 1	Castration Resistant Metastatic Prostate Cancer; Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

[225Ac]Ac-AKY-1189

Phase 1 · Active Modality: miniprotein radioconjugate (actinium-225)

Target Nectin-4

Indications

Locally advanced or metastatic urothelial cancer (UC) (Phase 1)
Nectin-4 expressing solid tumors (incl. breast, lung) (Phase 1)

Catalysts

— Q1 2027

Status note Lead program; IND cleared April 2025; multi-site Phase 1b in the U.S. ongoing. Eli Lilly collaboration covers generation of anticancer radiopharmaceuticals on the miniprotein platform, not this asset specifically.

[225Ac]Ac-AKY-2519

Preclinical · Active Modality: miniprotein radioconjugate (actinium-225)

Target B7-H3

Indications

B7-H3 expressing tumors (Preclinical)

Status note Advancing through IND-enabling studies into clinical trials; discovery/preclinical R&D spend line item.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	[225Ac]Ac-AKY-1189 (therapeutic)
Lead indication	Urothelial Carcinoma Bladder
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07020117	Phase 1	Recruiting	Sponsor	AKTS	—	Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma	—
NCT07581184	Phase 1	Recruiting	Sponsor	AKTS	—	Castration Resistant Metastatic Prostate Cancer; Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aktis Oncology, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	1,592,043	no change	0.44%	2026-08-14
Baker Bros. Advisors	996,351	no change	0.16%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AKTS — Aktis Oncology Inc.